Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved

Nat Rev Cardiol. 2021 Nov;18(11):737. doi: 10.1038/s41569-021-00627-z.
No abstract available

Publication types

  • Comment

MeSH terms

  • Benzhydryl Compounds / adverse effects
  • Glucosides / therapeutic use
  • Heart Failure* / drug therapy
  • Humans
  • Stroke Volume

Substances

  • Benzhydryl Compounds
  • Glucosides
  • empagliflozin